| Pluristem Therapeutics is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. Co.'s product candidates include: placenta expanded (PLX)-peripheral arterial disease, which is in a multinational clinical trial in critical limb ischemia, in recovery following surgery for hip fracture, and in the treatment of severe coronavirus-19 cases complicated by Acute Respiratory Distress Syndrome (ARS); and PLX-R18, which is under development in the United States for ARS, as well as in a trial in the United States and Israel for incomplete hematopoietic recovery following hematopoietic cell transplantation. We show 40 historical shares outstanding datapoints in our PSTI shares outstanding history coverage, used to compute PSTI market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing PSTI market cap history over the course of time is important for investors
interested in comparing PSTI's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of PSTI versus a peer is one thing; comparing
PSTI market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like PSTI can fluctuate over the course of history.
With this page we aim to empower investors researching PSTI by allowing them to research the PSTI market cap history.